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Abstract
Background: Multimorbidity is the co-occurrence of two or more diseases in the same individual. One method to
identify this condition at an early stage is the use of specific markers for various combinations of morbidities. Nonetheless,
evidence related to physiological markers in multimorbidity is limited. Objective: The aim was to perform a systematic
review to identify physiological markers associated with multimorbidity. Design: Articles available on PubMed, Register
of Controlled Trials, Academic Search Premier, CINAHL, Scopus, SocINDEX, Web of Science, LILACS, and SciELO, from
their inception to May 2018, were systematically searched and reviewed. The project was registered in PROSPERO under
the number CRD42017055522. Results: The systematic search identified 922 papers. After evaluation, 18 articles were
included in the full review reporting at least one physiological marker in coexisting diseases or which are strongly
associated with the presence of multimorbidity in the future. Only five of these studies examined multimorbidity in
general, identifying five physiological markers associated with multimorbidity, namely, dehydroepiandrosterone sulfate
(DHEAS), interleukin 6 (IL-6), C-reactive protein (CRP), lipoprotein (Lp), and cystatin C (Cyst-C). Conclusions: There is
a paucity of studies related to physiological markers in multimorbidity. DHEAS, IL-6, CRP, Lp, and Cyst-C could be the
initial focus for further investigation of physiological markers related to multimorbidity.
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Introduction
Multimorbidity is the co-occurrence of two or more dis-
eases in the same individual, which are often associated
with each other.1,2 It is more common in elderly,3 and it
affects one in five adults and two-thirds of the elderly.4,5
Multimorbidity is more prevalent in groups from lower
socioeconomic status.4 Although studies about multimor-
bidity have recently begun, evidence has already shown
that it leads to a decrease in quality of life,6 functional
decline,7 and an increased risk of mortality,8 in addition
to difficulty to manage it adequately. Early diagnosis and
management of multimorbidity may be important factors to
minimize serious consequences. One method to identify
this condition at an early stage is the use of specific phy-
siological and molecular markers for various combinations
of morbidities.9
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Some attempts have been made to identify physiological
markers associated with multimorbidity. Reviews have
evaluated markers that are associated with pairs of diseases.
For example, high levels of B-type natriuretic peptide are
commonly associated with dyspnea and have prognostic
value in the acute coronary syndromes, such as myocardial
infarction, diastolic dysfunction, and atrial fibrillation in
congestive heart failure patients.10 Cancer patients
frequently have obesity and diabetes as comorbidity con-
ditions. Current studies show that microRNAs such as miR-
9 may serve as novel biomarkers and molecular targets for
cancer therapy in patients with comorbidity conditions.11
Recently, other alternatives have been attempted to
improve early detection of multimorbidity. Alemi et al.
developed the multimorbidity index to account for the
prognosis of patients with multiple diagnoses. The authors
have reported that physiological markers may help not only
in the prevention of certain conditions and comorbidities
but also in the possibility of early diagnosis and treatment,
increasing the chances of survival of patients and decreas-
ing health expenditures.12,13
Using simple blood tests in hospital and/or outpatient
laboratories may be an easy-to-access alternative for the
population to detect specific physiological markers for a
set of diseases. As there are few studies evaluating markers
related to multiple concomitant diseases, the aim of this
article is to perform a systematic review to identify phy-
siological markers associated with multimorbidity.
Materials and methods
The search was conducted in the following electronic data-
bases: MEDLINE (via PubMed), Register of Controlled
Trials (Cochrane CENTRAL), Academic Search Premier,
CINAHL, Scopus, SocINDEX, Web of Science, LILACS,
and SciELO. The search was conducted in the first seme-
ster of 2018 and included all articles from the beginning of
the bases until May 2018. Manuscripts written in the fol-
lowing languages were included, English, Portuguese, or
Spanish. The Medical Subject Headings (MeSH) terms and
their synonyms were used to search the terms in all fields.
The search strategy used in PubMed is shown in Table 1.
The systematic review was reported according to the
PRISMA statement and the AMSTAR 2.14,15 According
to PICOS principles,14 we consider the following criteria:
P means any patient who presented multimorbidity; I
means patients with multimorbidity (who have two or more
coexisting diseases); C stands for patients who have none
or one disease; O means any physiological or molecular
marker; and S stands for the study design, mainly observa-
tional/epidemiological studies.
Observational studies, which evaluated molecular, phy-
siological, or genetic markers related to different multimor-
bidity, were selected. The inclusion criteria were studies
reporting specific markers to a condition of at least two
concomitant diseases. The exclusion criteria were papers
that did not specify the marker or were related to one spe-
cific disease; studies evaluating seasonal or allergic dis-
eases, general markers of oxidative stress, or markers of
resting metabolic rate; and reviews or papers in a language
other than English, Spanish, or Portuguese. Full texts of the
selected articles after screening the titles and abstracts were
assessed, and data were extracted using predetermined for-
mats. The extracted data included author(s) and year of the
publication, type of the study, sample, morbidities, and the
evaluated biomarkers.
Two independent researchers (GDF and JAS) performed
the literature search, screening titles and abstracts, full-
paper reviews, study quality assessment, and data extrac-
tion. Disagreements were referred to a third author.
The project was registered in PROSPERO under number
CRD42017055522.
Results
The search identified 922 papers. We found seven duplicate
studies and another 775 were excluded as they did not
include the outcome of interest. Thereafter, 140 papers
were screened to title and abstract selection, and 37 papers
were selected for full-text evaluation. Nineteen papers were
excluded for the following reasons: languages other than
English, Spanish, or Portuguese; literature review, case
study, or incomplete data. In the end, 18 papers reporting
at least one physiological marker with coexisting diseases
were included in the systematic review (Figure 1).
Tables 2 and 3 show the characteristics of the included
studies.
In relation to disease conditions, the studies are hetero-
geneous, and only five evaluated multimorbidity in a more
widespread construct (Table 2). Although only five studies
dealt exclusively with multimorbidity in general, our
search selected some studies, which associated markers for
specific comorbidities. We only considered papers evaluat-
ing at least two of the following diseases related to different
markers: three studies related renal and cardiovascular
disease, two studies with behavioral diseases, two with
bone diseases associated with periodontal diseases and
Alzheimer, one study related to depression and
Table 1. Literature search strategy used for the PubMed
database.
#1 “multimorbidity”[MeSH] OR “comorbidity” OR “co-
morbidity” OR “multicomorbidity” OR “multi-morbidity”
OR “-morbidity” OR “-morbid conditions” OR “multiple
diseases” OR “multiple morbidities” OR “multimorbid”
OR “multiple pathology” OR “disease clustering” OR
“chronic diseases” OR “Severity of Illness Index”
#2 “physiological markers” OR “Markers, Biological” OR
“molecular markers” OR “Biology, Molecular” OR
“Genetics, Molecular” OR “Molecular Genetic” OR
“Biochemical markers”
#3 #1 AND #2
2 Journal of Comorbidity
hypertension, one related to different cardiac conditions,
one related to psoriasis and metabolic comorbidities, one
study about infectious diseases, and two studies with
healthy people that evaluated markers predicting multi-
morbidity (Table 3).
Discussion
This article aims to review the literature to identify physio-
logical markers associated with patterns of multimorbidity.
Based on the systematic search, we found 18 studies from
2004 to 2017, which evaluated physiological markers
related to different concomitant diseases or which are
strongly associated with the presence of multimorbidity
in the future.
No randomized clinical trials (RCTs) were found in the
search strategy, most part of the studies carried out obser-
vational analyses, and none cited a methodology including
blind review. Nevertheless, from the 18 included studies,
15 presented a control group for comparability:
patients who had only one of the morbidities of the
study16–24,27,28,30,33 or without morbidity (matched accord-
ing to sex and age).19,26,29 Although all included papers
assessed association between at least two different morbid-
ities, only five assessed specifically markers for multimor-
bidity in general regardless of the disease. The three
studies, which did not present control groups, were related
to correlation between variables, which may increase the
risk of comorbidities.25,31,32 In general, even considering
that the included papers are not RCT or long follow-up
periods, the presence of a control group in most studies can
be used to assist with a more thorough data analysis. Nev-
ertheless, suggestions are put forward as the results are not
conclusive, because the aim is to observe cross-sectional
data. The quality evaluation of the studies followed the
parameters of the Newcastle–Ottawa scale.34
Physiological markers and multimorbidity
Only five studies evaluated multimorbidity in general. The
results cross-sectional data show that the elevated interleu-
kin 6 (IL-6) and lower dehydroepiandrosterone sulfate
(DHEAS) are associated with a greater burden of multi-
morbidity and suggest that investing in these markers may
be an alternative for earlier detection and target interven-
tions aimed at reducing multimorbidity.16 Although high
levels of serum cytokines such as IL-6 and tumor necrosis
factor a (TNF-a) are considered risk factors for several
chronic diseases, the second study emphasizes that these
markers are not available in the majority of clinical labora-
tories. Therefore, other markers should be studied, such as
C-reactive protein (CRP), lipoprotein (Lp), and cystatin C
(Cyst-C) levels. People in the group of those with zero or
one disease showed normal levels for the markers, as the
Figure 1. The flow diagram of studies included in the review.




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































number of chronic diseases increased the percentage of a
person with a normal value of the markers decreased, show-
ing that they are markers which can also be considered for
detection of multimorbidity.17 Three other studies also sug-
gested CRP as a possible marker for multimorbidity, asso-
ciating the increase of its concentration with two or more
chronic conditions.18–20 These data should be analyzed
with caution, because cross-sectional and longitudinal stud-
ies have limitations to identify cause or consequence.
Physiological markers, patterns of multimorbidity,
and specific combinations of diseases
In relation to the studies described in Table 3, combinations
of pairs of diseases were normally controlled by individuals
with only one of the associated diseases, thus observing the
pattern of specific markers between groups. Three studies
related renal and cardiovascular diseases. In ischemic heart
disease (IHD) and diabetes in end-stage renal disease
(ESRD) patients, it was observed that cardiac troponin T
(cTnT) was increased in IHD and diabetic patients com-
pared to control and isolated diseases, suggesting that
increased cTnT appears to be the most specific biochemical
marker to predict subclinical myocardial damage in ESRD
patients.21 It is suggested that chronic kidney disease
severely increases the risk of cardiovascular disease30;
however, it does not seem to be associated with mineral
bone disease.32
Two studies analyzed attention deficit hyperactivity dis-
order (ADHD) and conduct disorder (CD) comorbidity.
The genetic heterogeneity showed that variations in the
dopamine active transporter 1 (DAT1) gene confer signif-
icantly different risks to ADHD children to either have or
not have CD.23 These data corroborate with Gizer who
showed co-occurrence among psychiatric disorders and
that the candidate gene studies of psychological disorders
are involved in monoaminergic function (DAT1) giving the
relevance of these neurotransmitter systems to brain–beha-
vior relations.35 Taurines et al. also related monoaminergic
genes to comorbidities with autism spectrum disorders.27
One study reported different cardiac conditions and con-
cluded that the presence of coronary artery disease in mod-
erate aortic stenosis was associated with increased serum
osteoprotegerin (OPG) levels, suggesting the effect of
atherosclerosis on early valve calcification.28 Moreover,
one study evaluated depression and hypertension and
showed that decreased expression of heme oxygenase may
contribute to the risk of comorbidity of depression in hyper-
tension cases.33
Two studies reported osteoporosis with comorbidities. It
is clear that in Alzheimer’s disease there is an increase in
bone catabolism, associating the comorbidity of Alzhei-
mer’s disease with osteoporosis in the early disease course
detected at the level of biochemical blood markers, such as
C-terminal collagen fragments and osteocalcin.24 Other
comorbidity is periodontal disease, which is more common
in women with osteoporosis and is associated with lower
vitamin D and higher concentrations of RANKL and
OPG.26
Psoriasis and comorbidities (diabetes, obesity, heart dis-
ease, hypertension, and metabolic syndrome) can be eval-
uated with cathelicidin (LL-37) and vitamin D. Vitamin D
levels were lower in patients with psoriasis and comorbid-
ities, but serum LL-37 levels were significantly elevated.29
Furthermore, one study analyzed the coinfection of malaria
and HIV compared to HIV-infected individuals without
concurrent malaria infection and showed that serum iron
and albumin concentrations were indicators related with
malaria infection in HIV-infected subjects.22
Two studies with healthy people evaluating markers that
predict multimorbidity were included. In adolescents, the
establishment of retinol-binding protein 4 as a marker may
offer health-care providers a tool to begin aggressive pre-
ventive measures in those who are at increasing risk for
adiposity-related comorbidities but have not yet been
afflicted by them.25 In healthy men, significant correlations
were found between serum ferritin concentration and meta-
bolic syndrome parameters.31
Related findings
A birth cohort study aimed at assessing the association of
obesity with physiological markers at 22 years of age,
showing direct association for IL-6 and CRP and an inverse
association for adiponectin, suggesting early care for this
population at risk.36 A meta-analysis of prospective studies
suggests the association of IL-6 and CRP with type 2 dia-
betes risk (relative risk of 1.31 per 1 log pg/mL increment
in IL-6 levels and of 1.26 per 1 log mg/L increment in CRP
levels).37
Therefore, a systematic review has shown the eleva-
tion of the concentrations of pro-inflammatory cytokines
(IL-6, TNF-a) in metabolic syndrome, suggesting that
the measurement of these biomarkers may aid in the
detection of these disorders,38 and agrees with findings
from the past decade that have already indicated that
laboratory-measured pro-inflammatory markers are
needed to target specific treatment in the metabolic
syndrome.39
Limitations
As limitations of this study, the included papers were cross-
sectional analyses; however, it is not clear whether the
marker is a cause or a consequence related to different pairs
of diseases. In addition, only five studies are performed
with nonspecific concomitant diseases, showing the exist-
ing gap in the literature. Therefore, more studies control-
ling confounding variables and monitoring different
conditions are needed to find markers that allow the pre-
vention or early treatment of different multimorbidity.
8 Journal of Comorbidity
Conclusions
This study was important for grouping physiological mar-
kers associated with different types of comorbidities to
facilitate early diagnosis and intervention in these patients.
Nonetheless, there is a paucity of studies related to physio-
logical markers and multimorbidity. In the initial efforts,
despite cross-sectional analyses, DHEAS, IL-6, CRP, Lp,
and Cyst-C seem to be the choices for further investigation
regarding the effects of physiological markers related to
multimorbidity.
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3. Nunes BP, Thumé E and Facchini LA. Multimorbidity in
older adults: magnitude and challenges for the Brazilian
health system. BMC Public Health 2015; 15: 1172.
4. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of
multimorbidity and implications for health care, research, and
medical education: a cross-sectional study. Lancet 2012;
380(9836): 37–43.
5. Fortin M, Stewart M, Poitras ME, et al. A systematic review
of prevalence studies on multimorbidity: toward a more uni-
form methodology. Ann Fam Med 2012; 10(2): 142–151.
6. Fortin M, Lapointe L, Hudon C, et al. Multimorbidity and
quality of life in primary care: a systematic review. Health
Qual Life Outcomes 2004; 2: 51.
7. Ryan A, Wallace E, O’Hara P, et al. Multimorbidity and
functional decline in community-dwelling adults: a systema-
tic review. Health Qual Life Outcomes 2015; 13: 168.
8. Nunes BP, Flores TR, Mielke GI, et al. Multimorbidity and
mortality in older adults: a systematic review and meta-anal-
ysis. Arch Gerontol Geriatr 2016; 67: 130–138.
9. Sturmberg JP, Bennett JM, Martin CM, et al.
“Multimorbidity” as the manifestation of network distur-
bances. J Eval Clin Pract 2016; 23(1): 199–208.
10. Burke MA and Cotts WG. Interpretation of B-type natriuretic
peptide in cardiac disease and other comorbid conditions.
Heart Fail Rev 2007; 12: 23–36.
11. Ali AS, Ali S, Ahmad A, et al. Expression of microRNAs:
potential molecular link between obesity, diabetes and can-
cer. Obes Rev 2011; 12: 1050–1062.
12. Alemi F, Levy KR and Kheirbek RE. The multi-morbidity
index: a tool for assessing the prognosis of patients from
history of illness. eGEMs 2016; 4(1): 1235.
13. Zierer J, Pallister T, Tsai PC, et al. Exploring the molecular
basis of age-related disease comorbidities using a multi-
omics graphical model. Sci Rep 2016; 6: 37646.
14. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA state-
ment for reporting systematic reviews and meta-analyses of
studies that evaluate health care interventions: explanation
and elaboration. J Clin Epidemiol 2009; 62(10): e1–e34.
15. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical
appraisal tool for systematic reviews that include randomised
or non-randomised studies of healthcare interventions, or
both. BMJ 2017; 358: j4008.
16. Fabbri E, An Y, Zoli M, et al. Aging and the burden of multi-
morbidity: associations with inflammatory and anabolic hor-
monal biomarkers. J Gerontol A Biol Sci Med Sci 2015;
70(1): 63–70.
17. Garrafa E, Casnici N, Squazzoni F, et al. C-reactive protein,
lipoprotein (a) and cystatin C levels increase with multimor-
bidity in older persons. Eur J Intern Med 2017; 42: e25–e26.
18. Friedman EM, Christ SL and Mroczek DK. Inflammation
partially mediates the association of multimorbidity and func-
tional limitations in a national sample of middle-aged and
older adults: the MIDUS study. J Aging Health 2015;
27(5): 843–863.
19. Stepanova M, Rodriguez E, Birerdinc A, et al. Age-
independent rise of inflammatory scores may contribute to
accelerated aging in multi-morbidity. Oncotarget 2015; 6(3):
1414–1421.
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